RANDOMIZED PHASE II STUDY OF DOCETAXEL, ADRIAMYCIN AND CYTOXAN

多西他赛、阿霉素和环磷酰胺的随机 II 期研究

• 批准号: 7368184
• 负责人: GEORGE SOMLO
• 金额: $ 0.44万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7368184
• 关键词: RANDOMIZED; PHASE; II; STUDY; DOCETAXEL

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Neo-adjuvant chemotherapy may allow breast preservation and down staging in patients with primary breast cancer. Higher pathological complete response rates following neo-adjuvant chemotherapy may predict for prolonged survival. This study will attempt to define a less toxic and potentially more effective neo-adjuvant regiment in patients with both HER-2 positive and HER-2 negative Stage II-III breast carcinoma. This neo-adjuvant setting also allows for exploratory analysis of protein profiles, DNA and RNA profiles of the tumor and normal tissue prior to and subsequent to chemotherapy in order to identify predictive and prognostics indicators of outcomes and potential targets for future therapy. This project will represent multidisciplinary and translational research collaborations amongst the clinical and research entities of the City of Hope Comprehensive Cancer Center.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。新辅助化疗可以使原发性乳腺癌患者保留乳房并降低分期。新辅助化疗后较高的病理完全缓解率可能预示生存期延长。本研究将尝试在HER-2阳性和HER-2阴性的II-III期乳腺癌患者中定义毒性较小且可能更有效的新辅助治疗方案。这种新辅助治疗还允许在化疗之前和之后对肿瘤和正常组织的蛋白质谱、DNA和RNA谱进行探索性分析，以确定未来治疗的结果和潜在靶点的预测性和特异性指标。该项目将代表希望之城综合癌症中心的临床和研究实体之间的多学科和转化研究合作。